These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
266 related items for PubMed ID: 19862481
1. Intense accumulation of 18F-FDG, not enhancement on MRI, helps to guide the surgical biopsy accurately in soft tissue tumors. Park JH, Park EK, Kang CH, Kim CH, Choe JG, Noh W. Ann Nucl Med; 2009 Dec; 23(10):887-9. PubMed ID: 19862481 [Abstract] [Full Text] [Related]
2. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AM, Molenaar WM, Koops HS, Vaalburg W. J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056 [Abstract] [Full Text] [Related]
3. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours? Hain SF, O'Doherty MJ, Bingham J, Chinyama C, Smith MA. Nucl Med Commun; 2003 Nov; 24(11):1139-43. PubMed ID: 14569167 [Abstract] [Full Text] [Related]
4. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Eary JF, Conrad EU, Bruckner JD, Folpe A, Hunt KJ, Mankoff DA, Howlett AT. Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579 [Abstract] [Full Text] [Related]
5. Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial. Erfanian Y, Grueneisen J, Kirchner J, Wetter A, Podleska LE, Bauer S, Poeppel T, Forsting M, Herrmann K, Umutlu L. Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1823-1831. PubMed ID: 28567495 [Abstract] [Full Text] [Related]
6. Utility of positron emission tomography in sarcomas. Schuetze SM. Curr Opin Oncol; 2006 Jul; 18(4):369-73. PubMed ID: 16721133 [Abstract] [Full Text] [Related]
7. Surgical considerations when reporting MRI studies of soft tissue sarcoma of the limbs. De La Hoz Polo M, Dick E, Bhumbra R, Pollock R, Sandhu R, Saifuddin A. Skeletal Radiol; 2017 Dec; 46(12):1667-1678. PubMed ID: 28884363 [Abstract] [Full Text] [Related]
9. PROLONGED FEVER WITHOUT OBVIOUS ETIOLOGY FINALLY DIAGNOSED AS HIGH-GRADE SOFT TISSUE SARCOMA. Doroftei NA, de Visscher N. Rev Med Chir Soc Med Nat Iasi; 2016 Oct; 120(1):100-4. PubMed ID: 27125079 [Abstract] [Full Text] [Related]
10. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Phelps ME, Czernin J. J Nucl Med; 2010 Aug; 51(8):1174-81. PubMed ID: 20660389 [Abstract] [Full Text] [Related]
11. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU, Eary JF. Cancer; 2005 Jan 15; 103(2):339-48. PubMed ID: 15578712 [Abstract] [Full Text] [Related]
12. Small, superficial, indeterminate soft-tissue lesions as suspected sarcomas: is primary excision biopsy suitable? Khoo M, Pressney I, Hargunani R, Saifuddin A. Skeletal Radiol; 2017 Jul 15; 46(7):919-924. PubMed ID: 28361352 [Abstract] [Full Text] [Related]
13. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC. Clin Cancer Res; 2008 Feb 01; 14(3):715-20. PubMed ID: 18245531 [Abstract] [Full Text] [Related]
14. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH. Ann Nucl Med; 2008 Aug 01; 22(7):603-9. PubMed ID: 18756363 [Abstract] [Full Text] [Related]
15. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma. Vernon CB, Eary JF, Rubin BP, Conrad EU, Schuetze S. Skeletal Radiol; 2003 Mar 01; 32(3):139-42. PubMed ID: 12605277 [Abstract] [Full Text] [Related]
16. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas. Kasper B, Hohenberger P, Strauss LG, Dimitrakopoulou-Strauss A. Hell J Nucl Med; 2010 Mar 01; 13(1):40-4. PubMed ID: 20411170 [Abstract] [Full Text] [Related]
17. FDG-PET for evaluating musculoskeletal tumors: a review. Aoki J, Endo K, Watanabe H, Shinozaki T, Yanagawa T, Ahmed AR, Takagishi K. J Orthop Sci; 2003 Mar 01; 8(3):435-41. PubMed ID: 12768492 [Abstract] [Full Text] [Related]
18. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis. Okazumi S, Dimitrakopoulou-Strauss A, Schwarzbach MH, Strauss LG. Hell J Nucl Med; 2009 Mar 01; 12(3):223-8. PubMed ID: 19936332 [Abstract] [Full Text] [Related]
19. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, Mechtersheimer G, Lehnert T. J Nucl Med; 2001 May 01; 42(5):713-20. PubMed ID: 11337565 [Abstract] [Full Text] [Related]
20. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. Buck AK, Herrmann K, Büschenfelde CM, Juweid ME, Bischoff M, Glatting G, Weirich G, Möller P, Wester HJ, Scheidhauer K, Dechow T, Peschel C, Schwaiger M, Reske SN. Clin Cancer Res; 2008 May 15; 14(10):2970-7. PubMed ID: 18445694 [Abstract] [Full Text] [Related] Page: [Next] [New Search]